Thomas Simon James Crabtree

Thomas Simon James Crabtree

Auto-generated profile, based on publicly available information

Thomas Simon James Crabtree

Department of Diabetes & Endocrinology, Royal Derby Hospital, University Hospitals of Derby and Burton NHS Trusts, UK; School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Diabetes Care
Verified
Journal Article
Open access
PDF file
TCThomas S.J. Crabtree
Thomas S.J. Crabtree
TGTomás P. Griffin
Tomás P. Griffin
YYYew W. Yap
Yew W. Yap
PNParth Narendran
Parth Narendran
GGGeraldine Gallen
Geraldine Gallen
TCThe Abcd Closed-Loop Audit Contributors
The Abcd Closed-Loop Audit Contributors
OBJECTIVE: We explored longitudinal changes associated with switching to hybrid closed-loop (HCL) insulin delivery systems in adults with type 1 diabetes and elevated HbA1c levels despite the use of intermittently scanned continuous glucose monitoring (isCGM) and insulin pump therapy. RESEARCH DESIGN AND METHODS: We undertook a pragmatic, preplanned observational study of participants included in the National Health Service England closed-loop pilot. Adults using isCGM and insulin pump across 31 diabetes centers in England with an HbA1c ≥8.5% who were willing to commence HCL therapy were included. Outcomes included change in HbA1c, sensor glucometrics, diabetes distress score, Gold score (hypoglycemia awareness), acute event rates, and user opinion of HCL. RESULTS: In total, 570 HCL users were included (median age 40 [IQR 29–50] years, 67% female, and 85% White). Mean baseline HbA1c was 9.4 ± 0.9% (78.9 ± 9.1 mmol/mol) with a median follow-up of 5.1 (IQR 3.9–6.6) months. Of 520 users continuing HCL at follow-up, mean adjusted HbA1c reduced by 1.7% (95% CI 1.5, 1.8; P < 0.0001) (18.1 mmol/mol [95% CI 16.6, 19.6]; P < 0.0001). Time in range (70–180 mg/dL) increased from 34.2 to 61.9% (P < 0.001). Individuals with HbA1c of ≤58 mmol/mol rose from 0 to 39.4% (P < 0.0001), and those achieving ≥70% glucose time in range and <4% time below range increased from 0.8 to 28.2% (P < 0.0001). Almost all participants rated HCL therapy as having a positive impact on quality of life (94.7% [540 of 570]). CONCLUSIONS: Use of HCL is associated with improvements in HbA1c, time in range, hypoglycemia, and diabetes-related distress and quality of life in people with type 1 diabetes in the real world.

26 September 2022 in Diabetic Medicine
Verified
Journal Article
Open access
JSJane Speight
Jane Speight
PCPratik Choudhary
Pratik Choudhary
EWEmma G. Wilmot
Emma G. Wilmot
CHChristel Hendrieckx
Christel Hendrieckx
HFHannah Forde
Hannah Forde
RARamzi Ajjan
Ramzi Ajjan
Aims: To explore the association between the use of glycaemic technologies and person‐reported outcomes (PROs) in adults with type 1 diabetes (T1D).Methods: We included T1D and technology publications reporting on PROs since 2014. Only randomised controlled trials and cohort studies that used validated PRO measures (PROMs) were considered.Results: T1D studies reported on a broad range of validated PROMs, mainly as secondary outcome measures. Most studies examined continuous glucose monitoring (CGM), intermittently scanned CGM (isCGM), and the role of continuous subcutaneous insulin infusion (CSII), including sensor‐augmented CSII and closed loop systems. Generally, studies demonstrated a positive impact of technology on hypoglycaemia‐specific and diabetes‐specific PROs, including reduced fear of hypoglycaemia and diabetes distress, and greater satisfaction with diabetes treatment. In contrast, generic PROMs (including measures of health/functional status, emotional well‐being, depressive symptoms, and sleep quality) were less likely to demonstrate improvements associated with the use of glycaemic technologies. Several studies showed contradictory findings, which may relate to study design, population and length of follow‐up. Differences in PRO findings were apparent between randomised controlled trials and cohort studies, which may be due to different populations studied and/or disparity between trial and real‐world conditions.Conclusions: PROs are usually assessed as secondary outcomes in glycaemic technology studies. Hypoglycaemia‐specific and diabetes‐specific, but not generic, PROs show the benefits of glycaemic technologies, and deserve a more central role in future studies as well as routine clinical care.

1 January 2024 in Age and Ageing
Verified
Journal Article
Open access
PDF file
RARami Aldafas
Rami Aldafas
TCTomas Crabtree
Tomas Crabtree
MAMohammed Alkharaiji
Mohammed Alkharaiji
YVYana Vinogradova
Yana Vinogradova
IIIskandar Idris
Iskandar Idris
Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) reduce cardio-metabolic and renal outcomes in patients with type 2 diabetes (T2D) but their efficacy and safety in older or frail individuals remains unclear. We searched PubMed, Scopus, Web of Science, Cochrane CENTRA and Google Scholar and selected randomised controlled trials and observational studies comparing SGLT2Is versus placebo/other glucose-lowering agent for people with frailty or older individuals (>65 years) with T2D and heart failure (HF). Extracted data on the change in HbA1c % and safety outcomes were pooled in a random-effects meta-analysis model. We included data from 20 studies (22 reports; N = 77,083 patients). SGLT2Is did not significantly reduce HbA1c level (mean difference −0.13, 95%CI: −0.41 to 0.14). SGLT2Is were associated with a significant reduction in the risk of all-cause mortality (risk ratio (RR) 0.81, 95%CI: −0.69 to 0.95), cardiac death (RR 0.80, 95%CI: −0.94 to 0.69) and hospitalisation for heart failure (HHF) (RR 0.69, 95%CI: 0.59–0.81). However, SGLT2Is did not demonstrate significant effect in reducing in the risk of macrovascular events (acute coronary syndrome or cerebral vascular occlusion), renal progression/composite renal endpoint, acute kidney injury, worsening HF, atrial fibrillation or diabetic ketoacidosis. In older or frail patients with T2D and HF, SGLT2Is are consistently linked with a decrease in total mortality and the overall burden of cardiovascular (CV) events, including HHF events and cardiac death, but not protective for macrovascular death or renal events. Adverse events were more difficult to quantify but the risk of diabetic ketoacidosis or acute kidney injury was not significantly increase.

1 March 2019 in Practical Diabetes
Verified
Journal Article
Closed access
PDF file
TCThomas Sj Crabtree
Thomas Sj Crabtree
AMAlasdair McLay
Alasdair McLay
EWEmma G Wilmot
Emma G Wilmot

11 February 2020 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
DSDavid Shaw
David Shaw
TCT. S. J. Crabtree
T. S. J. Crabtree
PHP. Hammond
P. Hammond
AMA. McLay
A. McLay
EWEmma G. Wilmot
Emma G. Wilmot

1 June 2020 in British Journal of Diabetes
Verified
Journal Article
Closed access
PDF file
TCThomas Sj Crabtree
Thomas Sj Crabtree
RDRalph A DeFronzo
Ralph A DeFronzo
RRRobert E J Ryder
Robert E J Ryder
CBClifford J Bailey
Clifford J Bailey
Imeglimin is a novel, first in-class, blood glucose-lowering agent which acts via a mitochondrial mechanism to enhance glucose-induced insulin secretion, decrease hepatic glucose output and increase glucose uptake by skeletal muscle. A systematic review and meta-analysis of randomised controlled clinical trials (RCTs) with imeglimin in adults with type 2 diabetes was undertaken. Of 45 articles identified, five were RCTs but, due to the format of the data, only three could be combined in a meta-analysis (total n=180 participants). A random-effects model found that imeglimin 1500 mg twice daily as monotherapy and add-on to metformin or sitagliptin was associated with reductions of HbA1c by -0.63% (95% CI -0.84 to -0.42) (-6.6 mmol/mol, 95% CI -8.8 to -4.4) and reductions of fasting plasma glucose by -0.52 mmol/L (95% CI -0.80 to -0.24) compared with placebo. Adverse events were minimal, mostly gastrointestinal, and without hypoglycaemia. It is concluded that imeglimin displays promising improvements in HbA1c and fasting plasma glucose and is generally well tolerated.